FOXO Technologies ( (FOXO) ) has shared an update.
On April 17, 2025, FOXO Technologies Inc. announced a 1 for 10 reverse stock split of its Class A common stock, effective April 28, 2025. This move, approved by shareholders in November 2024, aims to comply with NYSE American’s listing requirements and is not expected to impact the company’s operations. The reverse split will adjust stock options, warrants, and equity incentive plans proportionately, ensuring uniform effects across all shareholders.
Spark’s Take on FOXO Stock
According to Spark, TipRanks’ AI Analyst, FOXO is a Underperform.
FOXO Technologies faces significant financial challenges, including ongoing losses and high leverage, which weigh heavily on its overall stock score. Technical analysis suggests bearish trends, while valuation metrics highlight profitability issues. However, recent corporate actions offer some optimism for future stability and growth.
To see Spark’s full report on FOXO stock, click here.
More about FOXO Technologies
FOXO Technologies Inc. operates in the healthcare and biotechnology sector, owning subsidiaries such as Rennova Community Health, Inc., Myrtle Recovery Centers, Inc., and Foxo Labs, Inc. The company focuses on providing healthcare services through hospitals and behavioral health facilities, as well as developing biotechnology solutions to improve human health and lifespan.
YTD Price Performance: -62.41%
Average Trading Volume: 7,477,750
Technical Sentiment Signal: Buy
Current Market Cap: $3.49M
See more insights into FOXO stock on TipRanks’ Stock Analysis page.